Finerenone Slows Kidney Decline in Non-Diabetic CKD Patients
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
Summary
A new randomized trial tested finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in adults with chronic kidney disease who do not have diabetes. Previously proven effective in diabetic CKD, finerenone was now studied in a broader population. Among 1,584 participants, those taking finerenone lost kidney function significantly more slowly than those on placebo — 3.3 vs. 4.0 ml/min/1.73m² per year. Finerenone also reduced the combined risk of major kidney or cardiovascular events by 23%. The main side effect was hyperkalemia, which caused treatment discontinuation in a small number of participants. These findings suggest finerenone's benefits extend well beyond diabetic patients, potentially transforming how non-diabetic CKD is managed.
Detailed Summary
Chronic kidney disease affects hundreds of millions worldwide, and until recently most proven therapies — including SGLT2 inhibitors and finerenone itself — were primarily studied in patients with diabetes. This landmark trial asks a critical question: does finerenone protect the kidneys and heart in CKD patients who do not have diabetes?
The FIND-CKD trial enrolled 1,584 adults with CKD (eGFR 25–90 ml/min/1.73m²) and significant albuminuria who were already on renin-angiotensin system inhibitors. Participants were randomized to finerenone 10 or 20 mg daily versus placebo. The primary endpoint was total eGFR slope — the mean annual rate of kidney function decline — over 32 months.
Finerenone significantly slowed kidney function loss: the annual eGFR decline was 3.3 ml/min/1.73m² in the finerenone group versus 4.0 in the placebo group, a statistically significant difference of 0.7 ml/min/1.73m² per year. The composite of kidney or cardiovascular events was reduced by 23% (HR 0.77, p=0.04). Individual kidney and cardiovascular composites trended toward benefit but did not reach significance individually, likely due to limited event numbers.
Hyperkalemia was the most notable adverse event, occurring in 17% of finerenone-treated patients versus 13.3% on placebo. Serious discontinuations due to hyperkalemia were rare (1.5% vs. 0.1%), and hospitalizations for hyperkalemia were low in both groups.
These results meaningfully expand the clinical utility of finerenone. Physicians managing non-diabetic CKD now have trial-level evidence supporting finerenone as a kidney-protective agent on top of standard therapy. Given the progressive nature of CKD and the limited toolkit for slowing its progression outside diabetes, this is a clinically significant development. Monitoring potassium levels remains essential when prescribing finerenone.
Key Findings
- Finerenone slowed annual eGFR decline by 0.7 ml/min/1.73m² vs. placebo in non-diabetic CKD (p<0.001).
- Combined kidney and cardiovascular event risk was reduced 23% with finerenone (HR 0.77, p=0.04).
- Hyperkalemia occurred in 17% of finerenone patients vs. 13.3% on placebo, with few serious cases.
- Benefits were seen in patients already on renin-angiotensin system inhibitors, suggesting additive protection.
- Trial extends finerenone's evidence base beyond diabetic CKD for the first time in a large RCT.
Methodology
FIND-CKD was a randomized, double-blind, placebo-controlled trial in 1,584 adults with non-diabetic CKD and albuminuria across international sites. The primary endpoint was total eGFR slope over 32 months using a two-slope linear spline mixed-effects model. Secondary composite endpoints were tested using prespecified hierarchical analysis to control Type I error.
Study Limitations
Summary is based on the abstract only, as the full paper is not open access. The individual kidney and cardiovascular composite endpoints did not achieve statistical significance separately, limiting interpretation. The trial was industry-funded by Bayer, which manufactures finerenone, introducing potential for bias.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.